U.S. halts distribution of Eli Lilly’s coronavirus antibody treatment bamlanivimab as a monotherapy

The U.S. government has halted distribution of Eli Lilly’s COVID-19 antibody treatment bamlanivimab (LY-CoV555) as a monotherapy just four months after it received FDA emergency use authorization, citing a sustained increase in variants of SARS-CoV-2 that are resistant to the monotherapy....More...

Progesterone therapy may improve coronavirus outcomes for men

Clinical Trial at Cedars-Sinai Suggests Injections of Female Hormone May Reduce Disease Severity in Certain Male Patients

COVID-19 disproportionately affects men compared with women, raising the possibility that a hormone like progesterone may improve clinical outcomes for certain hospitalized men with the disease.… ...More...